SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment #1
Under the Securities Exchange Act of 1934
ALTEON INC.
----------------------------
(Name of Issuer)
Common Stock par value $.01 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
02144G 10 7
-----------------
(CUSIP Number)
Rebecca R. Tilden
Vice President and Secretary
HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
(816) 966-4000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 16, 1998
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the
following box. [ ]
Page 1 of 4
There are no Exhibits
<PAGE> 2
CUSIP No. 02144G 10 7
___________________________________________________________________________
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ X ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 882,115
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 882,115
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 882,115
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 4.95%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
<PAGE> 3
This Amendment to the Statement on Schedule 13D (the "Schedule 13D") of HMR
Pharma, Inc., a Delaware corporation ("Parent"), with respect to the Common
Stock of Alteon, Inc. (the "Issuer"), is filed solely to report the
termination of Parent's obligation to report beneficial ownership of the
Issuer's Common Stock on Schedule 13D as a result of increases in the
number of shares outstanding of the Issuer.
Item 5(e) of the Statement on Schedule 13D of Parent is hereby amended
to read as follows:
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
- ------- -------------------------------------
(e) Parent ceased to be the possible deemed beneficial owner of more
than five percent of the Issuer's Common Stock on January 16, 1998.
<PAGE> 4
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
HMR PHARMA, INC.
Date: January 16, 1998 By: /s/ Rebecca R. Tilden
-----------------------------
Rebecca R. Tilden
Vice President and Secretary
